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ABSTRACT 
Public Health Significance: Antibiotic resistance is an increasingly important public 
health issue. Antibiotic resistance emerges from antibiotic use, and unnecessary and incorrect 
usage of these drugs is accelerating the increasing prevalence and severity of resistant organisms. 
Misdiagnosis of a urinary tract infection is one of the main causes of unnecessary antibiotic use. 
Problem Statement: Antibiotic overuse can lead to adverse patient outcomes, and 
antibiotics should be used judiciously and according to published treatment guidelines. Many 
clinicians at healthcare facilities do not adhere to treatment guidelines for asymptomatic 
bacteriuria; often clinicians incorrectly give asymptomatic patients a diagnosis of a urinary tract 
infection which has been shown to yield high rates of unnecessary antibiotic use. 
Objective: To determine whether the University Teaching Hospital adheres to IDSA 
treatment guidelines for UTI and ABU for this cohort of patients and explore the relationship 
between failure to adhere to IDSA guidelines of treatment of ABU and excess pharmaceutical 
costs. 
Setting: A public acute care teaching hospital affiliated with a local state university 
in central Texas. 
Linda Rose Frank, PhD, MSN 
OVERUSE OF ANTIBIOTICS FOR ASYMPTOMATIC BACTERIURIA IN A 
UNIVERSITY TEACHING HOSPITAL 
Emily Webster, MPH 
University of Pittsburgh, 2013
v 
Participants: Patients included in the cohort were at least 18 years of age and admitted 
to the hospital for >2 days between the dates of September 2011 and February 2012 and 
diagnosed with a UTI. 
Main outcome measures: Frequency of patients who were incorrectly diagnosed with a 
UTI who were asymptomatic and treated inappropriately, total number of antibiotics used for 
these patients, and the costs of these unnecessary antibiotics. 
Results: Of the 88 included patients, 26 patients (29.5%) had no documentation of any 
symptoms of a UTI but were diagnosed and treated inappropriately. There were a total of 353 
doses given to these patients for a total excess cost of $512.45. Eleven patients (12.5%) 
were classified as a “questionable” diagnosis of a UTI because documentation was not clear 
enough to indicate if the patient had a UTI or ABU. There were a total of 234 doses given to 
these patients for a total excess cost of $271.76. 
Conclusion: Based upon this sample, clinicians in this facility do not strictly adhere to 
IDSA treatment guidelines. The clinicians could benefit from an antibiotic stewardship program 
or an educational intervention to improve adherence to the current IDSA guidelines. 
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1.0  INTRODUCTION 
Globally, healthcare professionals are concerned about the increasing prevalence and incidence 
of antibiotic resistant organisms and their facility’s relationship with the emergence of resistance. 
Since antibiotic resistance is a product of antibiotic use, hospital systems need to be especially 
diligent in the monitoring of their rates of antibiotic use. One way of slowing the development of 
resistant organisms is to limit the amount of unnecessary antimicrobial prescriptions for patients 
who many not need treatment. Throughout the country, studies are finding high rates of 
asymptomatic bacteriuria (ABU) that is being improperly diagnosed as a urinary tract infection 
(UTI) and inappropriately treated with antibiotics. Recommendations for screening and treatment 
for ABU have been published by the Infectious Diseases Society of America (IDSA) guidelines. 
This project will review why inappropriate antibiotic use is an increasingly important 
public health problem that affects healthcare systems universally, and will analyze the existing 
literature of the overuse of antibiotics overall and also for patients with ABU. This project will 
also highlight the resulting harmful effects of overuse of antibiotic with a focus on increased 
adverse reactions, the emergence of antibiotic resistance, increased healthcare costs, and 
increased length of hospitalization.  
This study will assess one particular hospital’s adherence to treatment guidelines for 
ABU to determine their baseline rate of antibiotic prescription for patients who were 
asymptomatic and improperly diagnosed and treated with antibiotics for a UTI when no 
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treatment was recommended by IDSA. As a stewardship effort, a true assessment is needed of 
the rates of ABU and this University Teaching Hospital (UTH)’s compliance with the IDSA’s 
treatment guidelines in order to ensure the highest quality of care for all patients. This project 
will assess the need for future education of hospital staff at the UTH. Discussion of different 
types of antibiotic stewardship programs (ASP) that have been developed to combat 
antimicrobial overuse and its subsequent problems will be addressed, and recommendations will 
be suggested for the best intervention based on successes seen in other healthcare facilities for 
ABU overtreatment interventions. 
Based on recent findings in the literature and observations made by the clinical pharmacy 
specialists, our hypothesis is that clinicians at this hospital are not strictly adhering to the IDSA 
treatment guidelines and are treating asymptomatic patients unnecessarily. 
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2.0  BACKGROUND 
2.1 ANTIBIOTICS AND THE RISE OF ANTIBIOTIC RESISTANCE 
The increasing prevalence of antibiotic resistance is considered by the Centers for Disease 
Control and Prevention (CDC), the National Institutes of Health (NIH), and many scientists to be 
one of today’s most pressing public health problems. Resistance to almost every type of 
antimicrobial is increasing globally, and the emergence of pan-drug-resistant and extremely 
drug-resistant organisms is becoming more and more frequent.1 Common infections are 
becoming more difficult to treat, and resistant infections are becoming time-consuming and 
expensive to cure. Current antibiotics are becoming less effective, and the lack of antibiotic 
agents in development that could combat resistant organisms is even more problematic. 
When a patient uses antibiotics it applies selective pressures on internal bacteria and 
drives the emergence of resistant organisms. When a new antibiotic is introduced in a clinical 
setting, initially the targeted organism will be susceptible to the drug, and it will be prohibited 
from replicating or be killed.  As the antibiotic is used more frequently, bacteria develop ways to 
resist the drug’s effects and reduce their susceptibility. New strains have emerged and will 
continue to emerge with resistance to a drug or a whole drug class.2  
Since resistance arises with antibiotic use, it is important to use antibiotics as judiciously 
as possible. Antibiotic use is especially common in healthcare facilities. Antibiotics are the most 
4 
frequently used types of medications in the United States,3 and primary care is responsible for the 
majority of antibiotic prescriptions.4 Approximately 200 to 300 million prescriptions are written 
for antibiotics each year; 45% of these are for outpatient use, and around 25% of all hospitalized 
patients receive antibiotics.2 Inappropriate use of antibiotics, including inappropriate dosages and 
durations, or treating a patient with antibiotics when they should not have been treated is 
unnecessarily contributing to the problem. Studies have shown that “antibiotic use is unnecessary 
or inappropriate in as many as 50% of cases in the United States.”2 
Antibiotics used in one patient can have a tremendous impact on other patients in a 
healthcare facility and the larger society, unlike other medicines. As a result of antibiotics, 
resistant organisms can emerge and then spread to others; “thus, the use and misuse of these 
resources have ‘societal’ consequences’ that underscore the importance of stewardship in the 
hospital, community, and in long-term care facility populations.”1 
The rise of antibiotic resistance is an especially alarming public health problem because 
of the lagging development of new antibiotics. The problem is best summarized by Goff et al.: 
“Antibiotic resistance has exploded at the same time large pharmaceutical companies have 
reduced their research and development programs for newer agents with different mechanisms of 
action that might be useful in combating the emergence of resistance. Some investigators have 
described this as a ‘perfect storm’ for healthcare in the United States and other countries.”5 There 
isn’t any evidence that the immense need for new drugs against resistant organisms will be met 
anytime soon, reports that describe the future of the development of antibiotics provide little 
hope.6 It is increasingly important to use the antibiotics in existence as carefully as possible as to 
slow the development of resistant organisms.  
5 
A variety of antimicrobial agents are being tested in preclinical studies, but it is estimated 
that it will take at least 10 to 15 years before any will be available for routine because the 
pharmaceutical industry, both in the United States and globally, has slowed, and has not put forth 
as many resources to the development of drugs targeting the organisms that are causing the most 
problems. No agents that are targeting resistant gram-negative bacteria have entered the clinical 
development phase.2  
One of the reasons why development of antibiotics has slowed globally is “because all of 
the so-called easily exploitable bacterial binding sites have been exploited.”1 Gram-negative 
organisms are particularly complex. This makes development of a new antibiotic with a novel 
target or mechanism especially difficult because they have several ways to protect themselves 
from the toxic effects of antibiotic drugs.  A new drug would have to overcome several of these 
mechanisms in order to kill a bacterium or restrict its growth and replication.6  
Other factors impact the development of new antibiotics on the institutional level. 
Regulations strictly define the structure of clinical trials, which makes it difficult to test the 
efficacy of antibiotics that target gram-negative organisms in human trials, especially against 
rare and multi-drug resistant pathogens such as Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species. These are the gram-negative 
members of the so-called ESKAPE / ESCAPE pathogens.”6 The acronym ESKAPE or ESCAPE 
refers to the organisms that some scientists believe should be receiving the most focus, due to 
their increasing prevalence in healthcare facilities and their increasing resistance to the current 
antibiotics.5  
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Table 1: ESKAPE vs. ESCAPE Organisms 
 Organism  Organism 
E E. faecium E E. faecium 
S S. aureus S S. aureus 
K K. pneumoniae  C C. difficile  
A A. baumannii A A. baumannii 
P P. aeruginosa P P. aeruginosa 
E Enterbacter spp. E Enterobacteriaceae (includes K. pneumoniae, 
different species of Enterobacter, and E. coli) 
 
Although there are many factors that have been hindering the development of new 
pharmaceutical agents and progress is slow, there is still movement towards achieving a future 
with novel antibiotics. The pharmaceutical industry has recognized the intensity of the problem 
and is rising to meet the needs created by the “changing epidemiological landscape.”6 The 
American government has also recognized the severity of the antibiotic resistance and 
development problem, and is taking action to build a “sustainable research and development 
infrastructure to ensure the pipeline of new antibacterial agents.”6 In November 2009, President 
Barack Obama met with Swedish Prime Minister Fredrick Reinfeldt to establish a transatlantic 
task force with the European Union to address the issue of antibiotic resistance and develop 
strategies to improve the progress toward the development of new antimicrobial drugs.6  
2.2 EFFECTS OF INAPPROPRIATE ANTIBIOTIC USE 
There are risks associated with antibiotic use, but the high rates of inappropriate use increase 
these risks unnecessarily. The risks associated with antibiotic use are adverse reactions, 
7 
development of C. difficile infections, and the emergence of resistant organisms, which can lead 
to longer lengths of hospital stay, higher risks of mortality, and higher hospital costs. 
2.2.1 Adverse Reactions to Antibiotics 
Antibiotic use, whether appropriate or inappropriate, can potentially cause harmful reactions to 
an individual patient. Although antibiotics infrequently cause adverse effects, they are the second 
most common class of drugs to cause adverse drug reactions, second only to analgesics. Because 
they are some of the most commonly given drugs at healthcare facilities, the result is high 
numbers of antibiotic-associated adverse events,5 although they are usually considered to be 
mild.3  
The CDC reports that antibiotics cause over 140,000 emergency visits for patients with 
adverse reactions to their treatment.7 Studies using national databases estimated that antibiotics 
cause around “19% of ambulatory care visits and 18% of emergency department visits for drug-
related adverse events.”3 In a study of antibiotic related adverse events in emergency 
departments by Shehab et al., they found that the overall rate of emergency department visits for 
antibiotic-related adverse events was 10.5 visits per 10,000 outpatient prescription visits, which 
is half the rate of adverse events related to “high risk” medications like warfarin and insulin, but 
over 3 times higher than adverse events related to anticoagulant and antiplatelet drugs, oral 
hypoglycemic drugs, and “some narrow therapeutic index agents.”3 
Shehab et al. characterized the different types of antibiotic-associated adverse events into 
five different categories: adverse effects (diarrhea, headache, or dizziness), allergic reactions 
(immune responses such as rash or anaphylaxis), unintentional overdoses, unintentional 
exposures, and other effects (such as choking or injection site reactions).3 Of their study 
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population, almost 80% of drug-related adverse events were attributed to allergic reactions” and 
6.1% of drug-related adverse events led to hospitalization.3 
Unnecessary exposure to antibiotics increases the patient’s opportunities for harmful 
antibiotic-related adverse events. A study of antibiotic use in hospitals by Hecker et al., showed 
that 25% of unnecessary antimicrobial treatment regimens were associated with adverse effects 
or complications that were possibly attributable to the therapy.8 Most patients complained of 
gastrointestinal problems like nausea and diarrhea, but other patients developed UTIs, 
bacteremia with multi-drug resistant organisms, and C. difficile colitis after inappropriate 
antibiotic treatment regimens.8 The most effective way to reduce the majority of allergic 
reactions, other types of events, and emergency department visits is to minimize unnecessary or 
excessive exposures to antibiotics.3  
2.2.2 Clostridium difficile Infections 
Antibiotic use is one of the top risk factors for C. difficile infection in healthcare facilities.9 In 
fact, C. difficile causes 20-30% of antibiotic-associated diarrhea in hospitals, and is the primary 
cause for antibiotic-associated colitis.9 Antibiotics disrupt the normal flora in the colon, which 
renders the colon unprotected, leaving C. difficile with a new “niche” to flourish in.9 Longer 
treatment regimens, higher numbers of doses, and higher number of antibiotics used are all 
associated with a greater risk of C. difficile infection, although any exposure to antibiotics, short 
or long term, can increase a patient’s risk of infection.9 
C. difficile is a gram-positive, anaerobic organism that is commonly found in the natural 
environment,10 and it creates spores which can infect humans and be subsequently propagated 
through infected patients who shed the spores fecally.9,10 C. difficile can be isolated from 1-3% 
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of healthy adults10 but can be isolated from 7-26% of adult inpatients, and 20-50% of inpatients 
in facilities where there are endemic levels of C. difficile.9 The typical presentation of a 
symptomatic C. difficile is a mild diarrhea, but it can also cause a colitis which is potentially 
fatal. Although about 2% of cases result in death,9 according to the CDC, these infections cause 
around 14,000 deaths in the U.S. each year, which is at a historically high level.11 C. difficile 
spores are extremely difficult to kill because they are resistant to heat, acids, and many cleaning 
disinfectants, and can survive for months in the environment.10 The infection is spread via 
fomites shared between inpatients such as electronic rectal thermometers, toilets, and bedpans,9 
or through the hands of healthcare workers.10 
Studies reviewed by Cohen et al. show that 85%-96% of patients with symptomatic C. 
difficile infections had received antibiotics 14-28 days before the onset of symptoms.9 In another 
study of community-acquired pneumonia, 1 in 5 patients who were admitted to the ICU with a C. 
difficile infection were receiving antibiotics for pneumonia without any evidence of infection.1 In 
another ICU, 50% of patients who received antibiotics for community-acquired pneumonia that 
developed a C. difficile infection were determined later to not actually have pneumonia and were 
treated unnecessarily. One-third of these patients died from their C. difficile infection.1 
With high rates of inappropriate or indiscriminate use of antibiotics, it can be 
extrapolated that over-prescription behaviors will lead to higher rates of C. difficile infections, 
mortality, and healthcare costs. 
10 
2.2.3 Mortality 
Since inappropriate use of antibiotics leads to resistance, it is important to look at adverse events 
associated with resistance, although these effects are less immediate than poor drug reactions and 
C. difficile infections. 
Patients who are infected with an antibiotic resistant strain have higher rates of mortality 
compared to patients with susceptible strains. Cosgrove et al. have published a review detailing 
studies that have investigated mortality rates of resistant versus susceptible organisms involved 
in different types of infections. Significant findings are summarized in the table below. 
 
 
Table 2: Mortality for Resistant Organisms compared to Susceptible and Uninfected Patients 
Resistant 
organism 
Comparison 
organism 
Infection site Mortality 
indicator 
Value 
MRSA MSSA Bacteremia Odds ratio 1.93 
 MSSA Surgical 
wound 
90 day post-
operative 
mortality risk 
3.4 
 Uninfected Surgical 
wound 
90 day post-
operative 
mortality risk 
11.4 
VRE Uninfected Multiple sites Adjusted 
attributable 
mortality rate 
6% 
   Adjusted 
relative risk 
2.1 
P. aeruginosa Susceptible P. 
aeruginosa 
Multiple sites Relative Risk of 
mortality 
3 
Enterobacter 
spp. 
Susceptible 
Enterobacter 
spp. 
Multiple sites Relative risk of 
mortality 
5.02 
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Since the different authors cited in the review used different methods and mortality 
indicators, so it is difficult to compare the mortality associated with different organisms, but all 
indicators show that resistant organisms are related to higher risks and rates of mortality when 
compared to susceptible infections and uninfected patients.12 Results of a study by Roberts et al. 
echoes Cosgrove’s analysis: when comparing patients with antibiotic resistant infections to those 
without, 19.1% of patients with resistant infections died, compared with 3% of uninfected 
patients. This yields an adjusted mortality odds ratio of 2.16 and an attributable mortality rate of 
6.5%.13 Increases in mortality could be explained by a variety of factors, including increased 
need of surgery and other procedures, include increased odds of being sent to the ICU, a delay in 
treatment due to lack of effective antibiotics, and improper dosages, increased toxicity, and 
decreased effectiveness of drugs available for resistant organisms.12  
2.2.4 Length of Stay 
Antibiotic resistant infections are associated with increased length of hospitalization. A study 
by Goff et al. shows that patients with an antibiotic resistant infection have an average 
length of stay of 24.2 days, which is remarkable compared to the average length of stay for 
patients without a resistant infection, which is 8.0 days.5 A review of studies of the effects of 
antibiotic resistant infections demonstrates that many types of resistant infections are related to 
increased risks and longer hospital stays.  12, 13 
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Table 3: Increased length of hospital stay due to antibiotic resistant infections 
Resistant organism Comparison Attributable excess 
hospitalization days 
Risk of increased length 
of hospitalization 
MRSA bacteremia MSSA bacteremia 2 1.3 
VRE Uninfected 6.2 days n/a 
P. aeruginosa P. aeruginosa 5.7 days 1.7 
Enterobacter spp. Enterobacter spp. 9 1.5 
All resistant 
infections 
Uninfected 12.7 +/- 1.2 days n/a 
These studies depict a distinct longer length of stays for patients with resistant infections, 
ranging from 2 to 13 days of excess hospitalization time. This difference is most notable when 
compared with patients without any infection. Longer lengths of hospital stay attributed to 
resistant infections could be explained by the increased need for surgical interventions required 
in order to control infections.12 
2.2.5 Costs 
Healthcare in the United States is already very expensive. In 2013, it is estimated that 18.4% of 
the US gross domestic product will be spent on healthcare,5 and the overuse of antibiotics is only 
adding unnecessary costs to an already heavily burdened health system. The excess costs of 
antibiotics include the pharmaceutical costs, costs of hospitalizations attributed to resistant 
infections, and costs associated with treatment of C. difficile. 
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2.2.5.1 Costs of antibiotics 
Prices of the individual antibiotics add up to substantial pharmaceutical costs to 
healthcare facilities. The CDC reports that $1.1 billion dollars is spent every year on unnecessary 
antibiotics for adult upper respiratory infections alone.14 In a study of unnecessary antibiotic use 
by Hecker et al., researchers found the total average wholesale price of unnecessary antibiotics 
for study patients was almost $15,000, or an estimated yearly total of over $350,000.8 The 
antibiotic costs considered are relatively little compared to the total cost of care.1 
2.2.5.2 Hospitalization Costs 
It is important to consider the downstream costs of unnecessary antibiotic use. As 
previously described, antibiotic use leads to antibiotic resistance, which is directly linked to 
increased adverse effects, increased rates of C. difficile infections and colitis, and lengths of 
hospitalization. These result in higher costs incurred by patients at healthcare facilities. No data 
could be found to assess the costs of allergic reactions and other adverse antibiotic-associated 
drug events. 
Overall, it is estimated that the United States spends $5 billion each year for antibiotic 
resistant infections.5 Patients with antibiotic-resistant infections cost more per day to stay in the 
hospital compared to those without antibiotic-resistant infection ($2,098 vs. $1,581 per day).5 
The total cost of care for those with antibiotic resistant strains was higher compared to those 
without an antibiotic resistant strain ($58,029 vs. $13,210).5 
Several published reviews have investigated the differences in costs between patients that 
are infected with different types of resistant organisms compared with susceptible infections and 
patients without infections. The table below summarizes some of the notable findings of these 
reviews. 12, 13
14 
Table 4: Mean Attributable Hospital Costs due to Resistant Infections 
Infection Comparison Mean Attributable cost to 
resistant infection 
MRSA MSSA $13,901 
MRSA Uninfected $41,274 
VRE Uninfected $12,766 
Enterobacter spp. Susceptible Enterobacter spp. $29,379 
All ARI Uninfected $27,715 
This table clearly demonstrates that patients with antibiotic resistant infections are more 
expensive to treat than susceptible organisms; these differences are especially striking when 
comparing the costs to uninfected patients.  Costs could be higher due to longer lengths of stay in 
the hospital, increased need for surgeries, increased risk of hospital-acquired infections, and 
adverse reactions to treatments. Urinary tract infections will be the main focus of this project 
later, and according to Stone et al., the mean attributable cost of a hospital acquired urinary tract 
infection is $1006.15 
Although these numbers only reflect hospital costs, it is important to consider societal 
costs that are much more difficult to measure, such as loss of productivity, time spent away from 
the workplace, time spent away from family and friends, and stress. 
2.2.5.3 Costs of C. difficile infections 
C. difficile infections are very costly to the individual patient’s health, but it also costs the 
hospital a substantial amount to treat and care for the infected patient. An estimated $3.2 billion 
dollars is spent each year to treat C. difficile infections in the United States alone.9, 10 In a study 
15 
done in Massachusetts, $55.2 million was used to manage C. difficile infections in 55,380 
inpatient-days at the study hospital.9 
2.2.5.4 Medicare Retaliates 
The cost of antibiotic overuse has recently become more expensive for healthcare 
facilities. Hospital-acquired infections cost around $6.5 billion a year to treat, and much of this 
money is reimbursed to hospitals by Medicare and Medicaid.5 Beginning in October of 2008, the 
Centers for Medicare and Medicaid Services announced that it was no longer reimbursing 
hospitals for hospital-acquired infections in order to incentivize their reduction. The rationale 
behind this decision is that hospital-acquired infections are considered to be preventable, 
especially because there are a variety of evidence-based treatment guidelines to direct physicians 
and hospital staff on the proper ways to treat patients and protect them from nosocomial 
infections.5 Since antibiotics are improperly administered and often result in further infections 
and with resistant strains, hospitals now have an incentive to reduce the amount of patients who 
receive antibiotics unnecessarily because, should they develop a hospital acquired infection, they 
will not receive money for those patients who were covered with Medicare, which would be 
detrimental to the facility.5 
2.2.6 Urinary Tract Infections and Asymptomatic Bacteriuria 
Urinary tract infections (UTIs) are one of the most common infections that receive prescriptions 
for antibiotics each year.16 The IDSA’s definition of an acute uncomplicated UTI is a 
“symptomatic bladder infection characterized by frequency, urgency, dysuria, or suprapubic pain 
in a person with a normal genitourinary tract, and is associated with both genetic and behavioral 
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determinants.”17 A more complete and comprehensive definition of a UTI by the CDC and the 
National Healthcare Safety Network (NHSN) is provided in appendix A. UTIs are responsible 
for 35-40% of all nosocomial infections in North America, most commonly from a urinary 
catheter.18 Catheter-associated urinary tract infections (CAUTI) are the most common 
nosocomial infections. Approximately 560,000 CAUTIs are reported to the CDC each year,19 but 
it estimated that there are around 1 million cases in US hospitals and nursing homes each year.20  
A patient can be colonized with bacteria in their urinary tract but lack any symptoms of a 
UTI, which is known as asymptomatic bacteriuria (ABU). The IDSA definition of ABU is the 
“isolation of a specified quantitative count of bacteria in an appropriately collected urine 
specimen obtained from a person without symptoms or signs referable to urinary infection.”17 
For ABU, different organisms are more common depending on gender and age. E. coli is the 
most common organism found in women with ABU, and the strains of E. coli found in women 
with ABU have fewer virulence factors than strains typically isolated from women with a 
symptomatic UTI.17 Proteus mirabilis is more commonly found in men. Other strains commonly 
found in patients include Enterobacteriaceae (like K. pneumoniae), P. aeruginosa, Enterococcus 
species, and group B streptococci, many of these are previously listed in the ESCAPE/ESKAPE 
pathogens.17 ABU is common in many demographics, but its prevalence is different depending 
on a patient’s age, sex, sexual activity, the presence of genitourinary abnormalities, use of 
indwelling Foley catheters, and diabetes status. This prevalence data will be discussed in more 
detail.21 Catheter-associated bacteriuria is the most common hospital acquired infection 
worldwide.22  
Inaccurate diagnosis of UTIs is one of the leading causes of unnecessary antimicrobial 
exposure.18 In response, the IDSA has developed guidelines for the screening and treatment of 
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patients with ABU in order to help physicians make informed decisions for treatment based on 
evidence. Screening for ABU is only recommended if there are adverse outcomes (such as a 
development of a symptomatic UTI, bacteremia, sepsis, worsening functional status, progression 
to chronic kidney disease or hypertension, urinary tract cancer, or increased risk of mortality) 
that could be prevented by antibiotic treatment.17 The IDSA treatment guidelines are listed in the 
table below. 17 
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Table 5: IDSA recommendations for diagnosis and treatment of ABU in adults 
1. The diagnosis of asymptomatic bacteriuria should be based on results of culture of a
urine specimen collected in a manner that minimizes contamination.
• For asymptomatic women, bacteriuria is defined as 2 consecutive voided urine
specimens with isolation of the same bacterial strain in quantitative counts 105 
cfu/mL. 
• A single, clean-catch voided urine specimen with 1 bacterial species isolated in a
quantitative count 105 cfu/mL identifies bacteriuria in men. 
• A single catheterized urine specimen with 1 bacterial species isolated in a
quantitative count 102 cfu/mL identifies bacteriuria in women or men. 
2. Pyuria accompanying asymptomatic bacteriuria is not an indication for antimicrobial
treatment.
3. Pregnant women should be screened for bacteriuria by urine culture at least once in
early pregnancy, and they should be treated if the results are positive.
• The duration of antimicrobial therapy should be 3–7 days.
• Periodic screening for recurrent bacteriuria should be undertaken following therapy.
• No recommendation can be made for or against repeated screening of culture-
negative women in later pregnancy. 
4. Screening for and treatment of asymptomatic bacteriuria before transurethral
resection of the prostate is recommended.
• An assessment for the presence of bacteriuria should be obtained, so that results
will be available to direct antimicrobial therapy prior to the procedure. 
• Antimicrobial therapy should be initiated shortly before the procedure.
• Antimicrobial therapy should not be continued after the procedure, unless an
indwelling catheter remains in place. 
5. Screening for and treatment of asymptomatic bacteriuria is recommended before
other urologic procedures for which mucosal bleeding is anticipated.
6. Screening for or treatment of asymptomatic bacteriuria is not recommended for the
following persons.
• Premenopausal, nonpregnant women.
• Diabetic women.
• Older persons living in the community.
• Elderly, institutionalized subjects.
• Persons with spinal cord injury.
• Catheterized patients while the catheter remains in situ.
7. Antimicrobial treatment of asymptomatic women with catheter-acquired bacteriuria
that persists 48 h after indwelling catheter removal may be considered
8. No recommendation can be made for screening for or treatment of asymptomatic
bacteriuria in renal transplant or other solid organ transplant recipients.
The table below summarizes prevalence of ABU in different populations, and IDSA 
treatment recommendations. 17 Each group will be discussed more in depth. 
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Table 6: A summary of prevalence of ABU in different populations 
Population Prevalence, % 
Healthy, premenopausal women 1.0-5.0 
Pregnant women 1.9-9.5 
Healthy, young men 0-1.5 
Diabetic patients 
         Women 9.0-27 
         Men 0.7-11 
Elderly persons in the 
community 
         Women 10.8-16 
         Men 3.6-19 
Elderly persons in a long-term 
care facility 
         Women 25-50 
         Men 15-40 
Patients with spinal cord injuries 23-89 
Patients with indwelling catheter 
use 
    Short-term 9-23 
    Long-term 100 
Patients undergoing urologic 
procedure 
n/a 
Premenopausal, non-pregnant women have been found to have a prevalence of ABU 
between 1% and 5%.17 In this population, a urinary bacterial infection will usually resolve on its 
own. Although ABU is not associated with any long-term adverse outcomes, some data suggests 
that up to 30% of these women with ABU may develop a symptomatic UTI in the year following 
infection.21 However, treatment of ABU in this population does not decrease the frequency of 
subsequent UTIs.16 In fact, treatment of ABU in these women is “difficult, time consuming, 
costly, and potentially hazardous.”21 For these reasons, IDSA does not recommend the screening 
or treatment of ABU in non-pregnant, premenopausal women.17  
ABU prevalence in pregnant women ranges between 1.9% and 9.5%.17 Pregnant women 
with ABU are 20-30 times more likely to develop pyelonephritis during pregnancy compared to 
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pregnant women without ABU16 because “dilatation of the ureters and rental pelvis allow 
bacteria in the bladder to reach the kidneys.”21 Pyelonephritis can lead to premature delivery and 
babies with low birth weight.16 Treatment with antibiotics is associated with a 90% risk 
reduction of these poor fetal outcomes,21 so the IDSA recommends that all pregnant women 
should be screened and treated for ABU.17 
Women with diabetes have an ABU prevalence of 9% to 27%, more than 3 times higher 
than women without diabetes.17 Women with diabetes and ABU show no difference in the 
incidence of a subsequent UTI, mortality, or progression to diabetic complications when 
compared with women without ABU,16 so IDSA does not recommend the screening or treatment 
for ABU in diabetic women.17  
UTIs rarely occur in men,17 and the prevalence of ABU in young, healthy men ranges 
from 0% to 1.5% for both heterosexual men and men who have sex with men.21 Because of the 
rarity of these events, the IDSA does not consider ABU to be a relevant clinical issue and does 
not recommend screening or treatment for this population.17 
ABU in men with diabetes has a prevalence of 0.7% to 11%,17 although other sources say 
that men with diabetes show no differences in prevalence than men without diabetes.21 As with 
healthy young men, events are rare and screening and treatment for ABU is considered 
inappropriate.17 
The prevalence of ABU increases with age. Elderly patients have very high rates of ABU, 
and this prevalence differs depending on residence. The prevalence of ABU in elderly 
populations not in nursing homes or long term care facilities range between 10.8% to 16% in 
women, and 3.6 to 19% in men, and these rates increase with age.17 The prevalence is higher in 
“institutionalized” elderly patients living in long-term care facilities, which is between 25% and 
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50% in women, and between 15% and 40% in men.17 Studies did not see any difference in 
symptomatic episodes, morbidity, or mortality in elderly patients who were treated for ABU; in 
fact, elderly patients treated showed higher reinfection rates with antibiotic-resistant organisms 
and showed higher incidence of adverse drug reactions and side effects.21 Therefore, IDSA does 
not recommend screening or treating any elderly patients for ABU.17  
ABU is found in 23-89% of patients with spinal cord injuries.17 After treatment, almost 
all patients had recurrent bacteriuria with bacterial strains with increased antibiotic resistance,16 
so the IDSA does not recommend treatment for patients with spinal cord injuries.17 
Patients using catheters have high rates of ABU. In patients with short term 
catheterization (less than 30 days), the prevalence of ABU ranges between 9 and 23%17and 
increases daily by 2% to 7%.21 For patients with chronic indwelling catheters (longer than 30 
days), “bacteriuria is universal.”21 IDSA does not recommend for the screening or treatment of 
“catheterized patients while the catheter remains in situ,”17 but treatment should be considered 
for patients who have persistent ABU 48 hours after an indwelling catheter has been removed.17 
ABU in patients who undergo traumatic genitourinary procedures leads to bacteremia in 
60% of patients.23 Due to these findings, the IDSA recommends screening and treatment of 
patients before they undergo a “transurethral resection of the prostate” as well as before “other 
urologic procedures for which mucosal bleeding is anticipated.”17  
Although the IDSA guidelines clearly identify patients who should be treated and why, 
many ABU infections are treated as if they were UTIs or for completely inappropriate reasons. 
Pyuria is a common reason why physicians may treat ABU. The IDSA defines pyuria as “the 
presence of increased numbers of polymorphonuclear leukocytes in the urine and is evidence of 
an inflammatory response in the urinary tract.”17 However, 30% of healthy young women, 70% 
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of diabetic women, 90% of the institutionalized elderly, 90% of hemodialysis patients, and 30-
70% of pregnant women with ABU present with pyuria, so it is impossible to differentiate 
symptomatic from asymptomatic urinary tract infections based on pyuria alone.23 IDSA does not 
recommend treating any patient because they have pyuria.17 Physicians also commonly treat an 
asymptomatic patient for a UTI because they have cloudy or foul-smelling urine although 
“cloudy or foul smelling urine is not an indication for urinalysis, culture, or antimicrobial 
treatment.”16  
Why is overtreatment of ABU so common in healthcare facilities, especially if there are 
clear and specific treatment screening and treatment guidelines available? Evidence shows that 
guidelines are not followed very often and their creation and dissemination do not often result in 
a change in attitudes or practice.1 What are possible influences for this trend? 
First, it is important to look at factors influencing physicians to prescribe antibiotics. In a 
survey of physicians at the University of Miami Miller School of Medicine, Abbo et al. 
examined attitudes and reasons for antibiotic use.24 Almost all of the faculty and residents who 
responded acknowledged that antibiotics are misused locally and nationally, and recognized that 
misuse causes antibiotic resistance and was harmful to patients. They both noted that they were 
concerned about resistance in their hospital and society when they prescribed antibiotics.24 The 
survey found that the factors that most often influenced antibiotic use “were the risk of missing 
an infection and whether a patient is critically ill or immunocompromised.”24 When considering 
the prescription of an antibiotic, faculty members were concerned about the costs that the 
hospital would incur, and residents were “significantly more likely to be reassured when using an 
antibiotic even if it might be the wrong one.”24 More than one third of both faculty and residents 
rarely or did not consider the potential for a C. difficile infection when prescribing.”24 The most 
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interesting result of the study was that 62% of the physicians and residents who responded to the 
survey agreed that other doctors overprescribe antibiotics. However, only 13% of the same 
respondents “agreed that they themselves overprescribe antibiotics.”24 The survey did reveal that 
physicians and residents both wanted to receive “more education about antibiotics and feedback 
about their antibiotic selections.”24  
Communication with patients can influence antibiotic prescribing behaviors. It is well-
known that patients can pressure physicians to give antibiotics when it is often unnecessary. 
Studies show that patients do not usually think of resistance when considering the harmful 
consequences of antibiotic use, and many patients do not understand when antibiotics are 
biologically necessary (i.e. thinking antibiotics are effective against viral infections).3 Physicians 
have “reported difficulty with communicating information on antibiotic effectiveness and 
resistance” and sometimes feel that they do not have enough time with a patient to explain the 
risks associated with resistance and antibiotic overuse.3  
When specifically investigating prescribing practices for UTIs, some physicians reported 
that they prescribed antibiotics based on the information provided by the nursing staff and 
without ever assessing the patient’s symptoms themselves.25 Many physicians were unaware of 
IDSA guidelines for screening and treatment of ABU and thought that patients with ABU would 
benefit from therapy.25 Physicians were also concerned that “that their clinical decision making 
might be questioned if patients with ABU were not treated and then developed a symptomatic 
UTI.”25  
Changing definitions of UTIs as a HAI are affecting the prevalence rates seen in 
healthcare facilities. In March of 2012, the CDC/NHSN sent out a newsletter that said that 
because fever can be attributed to many different HAIs, like CAUTIs and pneumonia, it is 
24 
impossible to distinguish which infection is the root cause, it must be attributed to both causes.26 
This change in definition attempts to prevent healthcare facilities from “gaming” the system and 
selectively choosing which type of HAI to attribute the fever to so that it is not included in public 
reporting.26 This definition change will cause more physicians to diagnose and treat patients for a 
UTI although that patient may have ABU and the fever is due to another reason; in turn, this will 
lead to artificial inflation in the number of CAUTIs diagnosed and treated, leading to 
unnecessary exposures to antibiotics. 
In summary, antibiotic use has the potential to lead to adverse health events for patients 
in healthcare facilities, including the emergence of antibiotic resistance, which is an increasingly 
important public health issue. Unnecessary antibiotic use accelerates this process, so it is 
necessary to examine antibiotic prescription practices as the key determinant of this problem. 
Because the realm of infections is so broad, urinary tract infections and asymptomatic bacteriuria 
will be examined more closely. Reasons for choosing UTIs and ABU are that UTIs comprise a 
majority of all healthcare associated infections and because inaccurate diagnosis of UTIs is one 
of the leading causes of unnecessary antimicrobial exposure because ABU is often misdiagnosed 
as a UTI. Since treatment guidelines exist for patients with ABU, an investigation of the extent 
that a facility adheres to these guidelines could help a facility direct attention and resources to 
this issue to help reduce unnecessary antibiotic use. 
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3.0  METHODS 
3.1.1 Study Objectives 
The primary objective of this study was to determine the frequency of people that were 
diagnosed with and received antibiotic treatment for a UTI who lacked documentation of UTI 
signs and symptoms. For this study, these patients without documentation of UTI symptoms are 
considered to have ABU, and this study examined how many of these ABU patients received 
antibiotics inappropriately. A secondary outcome of this study was to determine the excess 
pharmaceutical costs that this hospital spent on antibiotics that were administered 
inappropriately.  
3.1.2 Study Design 
This study is a retrospective chart review of all patients admitted to the University Teaching 
Hospital (UTH) with a hospital stay of longer than 2 days for which a urine culture was obtained 
and a diagnosis of a UTI was made between September 2011 and February 2012.  
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3.1.3 Study Area 
The UTH, at which this data was collected, will be kept anonymous on request of the principal 
investigator. This study was developed as a quality improvement measure, and, based on local 
requirements, was exempt from formal submission to the network’s Institutional Review Board 
(IRB). It is important to note that although formal IRB approval was not necessary for data 
collection, the study was approved by both the infection control staff and the department of 
pharmacy. Data collection and analysis protocols were overseen and approved by the hospital’s 
clinical pharmacy infectious diseases specialists. The data was analyzed at both the UTH and at 
the University of Pittsburgh. Because this data set contained information collected from human 
subjects, the analysis of this data has been approved as an exempt study by the University of 
Pittsburgh IRB (IRB# PRO12100220). 
Though the hospital name will remain anonymous, it is important to note several features 
of the facility. The UTH is part of a large network of hospitals, but this particular facility is a 
250-bed public acute care teaching hospital that is affiliated with a local state university in 
central Texas with a case mix index of 1.7279. The hospital also serves as a Level I Trauma 
Center. 
3.1.4 Study Population 
3.1.4.1 Eligibility Criteria 
To be included in the analysis, the patient had to be at least 18 years of age and admitted 
to the hospital for >2 days between the dates of September 2011 and February 2012.  To be 
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eligible, the subject needed a discharge code of one of the following International Classification 
of Diseases, Ninth Revision (ICD-9) codes: 
Table 7: ICD-9 Codes Eligible for Study 
Code Definition 
595.0 Acute cystitis 
595.2* Other chronic cystitis 
595.4* Cystitis in diseases classified elsewhere 
595.89* Other specified types of cystitis 
595.9 Cystitis unspecified 
599.0 Urinary tract infection, site not specified (majority) 
599.9* Unspecified disorder of urethra and urinary tract 
601.0 Acute prostatitis 
601.1* Chronic prostatitis 
601.2 Abscess of prostate 
601.3* Prostatocystitis 
601.4* Prostatitis in diseases classified elsewhere 
601.8* Other specified inflammatory diseases of prostate 
601.9* Prostatitis unspecified 
602.9* Unspecified disorder of prostate 
603.1* Infected hydrocele 
603.8* Other specified types of hydrocele 
603.9 Hydrocele unspecified 
604.0 Orchitis epididymitis and epididymo-orchitis with abscess 
604.99 Other orchitis epididymitis and epididymo-orchitis without abscess 
607.1* Balanoposthitis 
607.2* Other inflammatory disorders of penis 
607.8* Various Disorders of penis 
607.9* Unspecified disorder of penis 
608.0* Seminal vesiculitis 
608.4 Other inflammatory disorders of male genital organs 
608.8* Other specified disorders of male genital organs 
608.9* Unspecified disorder of male genital organs 
616* Cervicitis, endocervicitis, vaginitis, vulvovaginitis 
Code definitions are from the Centers of Medicare and Medicaid.27 These codes 
encompass the full spectrum of cases that could be presenting with symptoms similar to those of 
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a UTI. After the search was done, no records were found for several of the ICD-9 codes, which 
are indicated with an asterisk.  
3.1.4.2 Inclusion Criteria 
To be included in this study, the eligible patients must have had a diagnosis of a UTI 
according to progress notes and discharge reports, in order to eliminate patients whose discharge 
ICD-9 codes were miscoded. 
3.1.4.3 Exclusion Criteria 
There are several groups of patients who should receive treatment for ABU according to 
IDSA guidelines. These patients were excluded in order to evaluate how many people with ABU 
were receiving inappropriate treatment. These groups included pregnant women, and patients 
admitted for a urologic procedure. Immunocompromised patients, indicated by moderate to 
severe levels of neutropenia, were also excluded because of special issues regarding treatment. 
Patients who were taking antibiotics upon admission or were diagnosed with a concomitant 
infection that required antibiotics were also excluded. Patients who had urine cultures taken 
during a stay in the ICU were excluded because the clinical pharmacy specialists felt the 
documentation of ICU patients was too complex to determine the appropriateness of a UTI 
diagnosis and treatment.  
3.1.4.4 The Population 
Figure 1 below depicts the breakdown of patients who were eligible, included, and 
excluded from the study. There were a total number of 237 eligible patients based on age, length 
of stay, and ICD-9 code requirements.  Of these, 7 patients were deemed to be miscoded. Of the 
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230 included patients, 142 patients were excluded from analysis, leaving 88 patients in the 
analysis. The patients’ charts were then classified into four different categories: the excluded 
patients, patients with UTIs, patients with ABU, and patients with a questionable UTI diagnosis. 
Patients whose records that were not clearly indicative of a UTI were reviewed carefully by an 
infectious disease specialist. The clinical infectious disease specialists made the final decision if 
the more vague symptoms, like fever, altered mental status, and abdominal pain, listed were 
explained by other causes or if the patient was asymptomatic. There were several cases in which 
there were listed symptoms that could be indicative of a UTI but could also be explained by 
other illness or circumstances, and the charts did not give a clear picture the patient truly had a 
UTI or not.  These were labeled as “questionable.”   
Figure 1: Summary of Study Participants 
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3.1.5 Data Collection 
Patient information was accessed via the UTH’s electronic record system, which presented all of 
the nurses’ observation notes, admission notes, progress notes, consultation notes, and discharge 
notes and summary for each patient encounter.  Information was documented on a data collection 
sheet found in appendix B.  The charts were reviewed to examine different elements:  
demographics, signs and symptoms of a UTI, lab values, and patient response variables.  The 
variables chosen for collection were based on a compilation of variables that were collected in 
similar published studies.18-19, 28-32 
Demographic variables collected included age, sex, comorbidities, and catheter use, 
including catheter type and duration of use.  The signs and symptom variables that were 
collected included the highest temperature during the length of stay, dysuria (burning during 
urination), increased frequency of urination, urgency of urination, costovertebral angle 
tenderness, suprapubic pain or tenderness, flank pain, and altered mental status. The lab values 
collected included serum white blood cell count, the type of organism found from the urine 
culture, the amount of bacteria found (cfu/ul), and the results of the urinalysis (UA), specifically 
the white blood cell count in the urine.  The WBC count noted was the one done closest to the 
time that the urine culture was taken. The patient response variables collected include the dosage 
and duration of treatment, and the antibiotics prescribed for the UTI. A price list of the 
antibiotics was obtained from the hospital’s pharmacy and is included in appendix C. 
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3.1.6 Data analysis 
Most of the analysis was calculated using Microsoft Excel. Information collected from all the 
groups was the frequency of the organisms isolated from urine cultures, symptoms found in 
patients, reasons for culture and treatment, and these will also be calculated as percentages. The 
dates of hospital admission and discharge were recorded to calculate length of stay, and the 
date of urine culture and date of treatment initiation were collected to calculate the length of 
time between culture and treatment. Dates of hospitalization, culture, catheter insertion and 
removal were collected to speculate whether colonization was catheter-acquired. Over 2 
days of hospitalization or catheter use prior to culture was presumed to be a case of hospital-
acquired or catheter-acquired bacteriuria, respectively. The total number of doses of 
antibiotics was added for the ABU and questionable groups, and when multiplied by the price of 
the antibiotic, the total costs of excess pharmaceuticals will be obtained. Defined Daily Doses 
per 1000 patient days was calculated as well as antibiotic days per 1000 patient days.  
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4.0  RESULTS 
4.1 EXCLUDED GROUP 
Of the 230 eligible patients, 142 patients were excluded from the study. The most common 
reasons for exclusion were diagnosis with a concomitant infection that required an antibiotic 
treatment, having a urine culture taken while admitted in the ICU, and taking antibiotics at the 
time of admittance. Exclusion information is summarized in Table 8. 
Table 8: Reasons for Exclusion from Study 
Reason for Exclusion No. Patients (%) 
Concomitant infections requiring 
antibiotics 
79 (55.6%) 
ICU at time of urine culture 29 (20.4%) 
Taking antibiotics on admittance 21 (14.8%) 
Pregnant 7 (4.9%) 
Planned urological procedure 5 (3.5%) 
Neutropenia 1 (0.7%) 
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4.2 INCLUDED PATIENTS 
The included patients were categorized into 3 groups: patients with clear and documented 
symptoms of a UTI, those with undocumented symptoms of a UTI and considered to have ABU, 
and those whose diagnosis of UTI was questionable.  The groups were very similar in terms of 
demographics. The mean age of all groups was in the 60s, although the patients were on average 
older in the ABU group than in the UTI group, and oldest in the questionable categories. All 3 
groups had higher numbers of women than men, which is expected since women have ABU and 
UTIs more often than men in the literature. Most patients in the ABU group appear to have 
acquired bacteria from the community prior to entering the hospital, but several members of the 
ABU and questionable group appear to have acquired their bacteriuria during their hospital stay 
(9 and 7 respectively), and some from catheters  (4 and 5 respectively) during their stay at the 
UTH.  
Table 9: Summary of demographics of included patients 
UTI ABU Questionable 
Average age 60.8 65.7 68.4 
% Female 66.7% 76.9% 63.6% 
Hospital-acquired n/a 9 (34.6%) 7 (63.6%) 
Catheter-acquired n/a 4 (15.4%) 5 (45.5%) 
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4.2.1 UTI Group 
Of the 88 included patients, 51 patients (58%) had clear, documented symptoms of a UTI. 
E. coli was isolated in almost half (47%) of patients, which was expected based on the 
literature.  The other most common organisms isolated from patients were E. faecalis and P. 
mirabilis. A complete list of isolated organisms can be found below. 
Table 10: Organisms Isolated from Patients with UTIs 
Organisms in Urine Culture No. 
Patients 
Escherichia coli 24 
Enterococcus faecalis 6 
Proteus mirabilis 3 
Citrobacter koseri 2 
Enterobacter aerogenes 2 
Klebsiella pneumoniae 2 
Streptococcus viridans 2 
Enterobacter clocae 1 
Enterococcus faecium 1 
Pseudomonas aeruginosa 1 
Salmonella enterica 1 
Staphylococcus haemolyticus 1 
Staphylococcus epidermidis 1 
No culture taken 1 
Mixed growth (probable contamination) 10 
The most common symptom seen in these patients was burning during urination (51%), 
followed by urinary frequency (33%). 24 patients had at least 2 concurrent symptoms (47%), and 
8 patients had at least 3 symptoms (16%).  
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Table 11: Symptoms seen in patients with UTIs 
Symptom No. Patients (%) 
Burning during urination 26 (50.9%) 
Urinary frequency 17 (33.3%) 
Flank pain 8 (15.7%) 
Suprapubic pain/tenderness 8 (15.7%) 
Altered Mental Status 8 (15.7%) 
Urinary urgency 7 (13.7%) 
Fever >100˚F 5 (9.8%) 
Costovertebral Angle Tenderness 4 (7.8%) 
2+ Symptoms 24 (47.1%) 
3+ Symptoms 8 (15.7%) 
4.2.2 ABU Group 
Of the 88 included patients, 26 patients (29.5%) had no documentation of any symptoms of a 
UTI but were diagnosed and treated for one according to progress notes, discharge summary, and 
the pharmacy logs. These patients were considered to have ABU and not a UTI in this analysis. 
The most common organisms isolated from urine cultures from these patients was E. coli 
(42%), which was similar to patients who had clear UTIs. The other most common organisms 
isolated were K. pneumoniae and S. epidermidis. Overall, organisms were very similar between 
the two groups. A complete list of organisms isolated from this group of patients can be found 
below. 
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Table 12: Organisms isolated from patients with ABU 
Organisms in urine culture No. Patients 
Escherichia coli 11 
Klebsiella pneumoniae 4 
Staphylococcus epidermidis 3 
Enterococcus faecalis 2 
Alpha  hemolytic Streptococcus 1 
Candida albicans/dubliniensis 1 
Enterobacter clocae 1 
Klebsiella oxytoca 1 
MRSA 1 
Pseudomonas aeruginosa 1 
No culture taken 1 
No growth 2 
Mixed growth (probable contamination) 3 
Twelve of the 26 patients in this group (46%) had no documented symptoms of a UTI 
anywhere in their charts. The remaining 14 patients displayed more unspecific symptoms of a 
UTI that were ruled by the clinical pharmacy specialists to be attributable to other causes. The 
most common of these was altered mental status, which could be explained by the following 
reasons: in this case mental illness, schizoaffective disorder, head injuries, heroin withdrawal, 
cocaine abuse, and alcohol withdrawal.  According to the clinical pharmacy specialists, the 
fevers seen by the patients in this group were mostly post-operative or due to other medical 
problems and were likely not caused by urinary bacteria.  Pain and tenderness in the flank and 
suprapubic regions were explained by ascites in the liver, benign prostatic hyperplasia, and 
injuries sustained from falls. 
Table 13: Symptoms in patients with ABU explained by other reasons 
Symptom No. patients (%) 
No symptoms documented 12 (46.2%) 
Altered mental status 9 (34.6%) 
Fever > 100˚F 4 (15.4%) 
Suprapubic Pain/tenderness 3 (11.5%) 
Flank pain 2 (7.7%) 
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Since no symptoms could be found, or the symptoms could be explained by other 
reasons, the medical records were searched for documented reasons why a UA was performed or 
why a urine culture was collected. Of the 26 patients, the records for 14 patients (56%) had no 
mention of why a UA was done and a urine culture was taken. For 3 patients, the UA/culture was 
done because the patient presented with a fever or altered mental status. For 3 patients, the 
UA/culture was done because of an abnormal color or smell of the urine, and for 2 patients, a 
UA/culture was done because there was blood in the patient’s urine. Other reasons a UA/culture 
was taken was because of a patient’s history of a UTI with chronic catheterization, urinary 
retention, low sodium levels, and because the Foley catheter was originally inserted in the wrong 
place.  
Table 14: Reasons for screening in patients with ABU 
Reasons for UA and Culture No. Patients (%) 
No reason noted 14 (53.8%) 
AMS/Fever 3 (11.5%) 
Abnormal urine color/smell 3 (11.5%) 
Bloody urine 2 (7.7%) 
Other 4 (15.4%) 
Medical records were also searched to find a reason why these patients were diagnosed 
and treated for a UTI if there were undocumented or unspecific symptoms. Most patients 
received treatment for a UTI based on “a positive UA result” (53.8%). According to the clinical 
pharmacy specialists and Gandhi et al., a UA is considered positive if there are over 10 WBC/hpf 
counted, which would mean only 5 UA’s were actually positive.30 Five patients were treated for 
a UTI because they had a “positive urine culture” (19.2%), and no reason for treatment was 
documented for 7 patients (26.9%). What is particularly interesting is that in 3 charts, the 
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physician’s notes specifically stated that the patient was asymptomatic, but would treat with 
antibiotics because of a foul smell in the urine, weakness, and positive culture. 
Table 15: Reasons for treatment for patients with ABU 
Reasons for Treatment No. Patients (%) 
Positive UA 14 (53.8%) 
- 0 to 2 WBC 1 
- 6 to 10 WBC 7 
- 21 to 50 WBC 1 
- 50 to 100 WBC 1 
- “Occasional” 1 
- “Too numerous” 3 
Positive culture 5 (19.2%) 
No reason documented 7 (26.9%) 
** 3 patient’s records noted specifically that the patient was 
asymptomatic, but treatment was initiated anyway 
From the charts, it was possible to determine if the patient was treated the same day as 
the culture and UA were taken. Interestingly, 21 of 26 patients (81%) of patients were given 
antibiotics at the same time as the urine culture was taken, and only for 5 patients did the 
physicians wait 2-4 days for culture results came back from the lab.  
Table 16: Time between culture and treatment in patients with ABU 
Time between culture and treatment No. Patients (%) 
Treatment initiated at time of culture 21 (80.8%) 
Waited 2-4 days for results 5 (19.2%) 
In total, the patients were treated for 99.5 antibiotic days and the length of stay for all 
patients was 187 days, which totals to 532.09 antibiotic-days/1000 patient days. 
The following table calculates the defined daily doses (DDD) and DDD/1000 patient-
days. The WHO DDD values were obtained from the WHO Collaborating Centre for Drugs 
Statistics Methodology.33 
39 
Table 17: Defined Daily Doses for patients with ABU 
Drug Code WHO 
DDD 
Total 
# 
Doses 
Dose in g Quantity 
dispensed 
(g) (Total 
# Doses x 
Dose in 
g) 
DDD's 
(Quantity 
Dispensed/WHO 
DDD) 
DDD/1000 
patient 
days 
Amoxicillin/ 
clavulanate 
(Augmentin) 
(875 mg) 
J01CR02 3 5 0.875 4.375 1.46 7.80 
Cefazolin 
(Ancef) (1000 
mg) 
J01DB04 3 65 1 65 21.67 115.86 
Cefepime (1000 
mg) 
J01DE01 2 18 1 18 9.00 48.13 
Ceftriaxone 
(Rocephin) 
(1000 mg) 
J01DD04 2 12 1 12 6.00 32.09 
Cefuroxime (250 
mg) 
J01DC02 3 4 0.25 1 0.33 1.78 
Cephalexin (500 
mg) 
J01DB01 2 1 0.5 0.5 0.25 1.34 
Ciprofloxacin 
(500 mg) 
J01MA02 0.5 31 0.5 15.5 31.00 165.78 
Meropenem (500 
mg) 
J01DH02 2 3 0.5 1.5 0.75 4.01 
Nitrofurantoin 
(100 mg) 
J01XE01 0.2 14 0.1 1.4 7.00 37.43 
Piperacillin/ 
tazobactam 
(Zosyn) (2250 
mg) 
J01CR05 14 20 2.25 45 3.21 17.19 
Piperacillin/ 
tazobactam 
(Zosyn) (4500 
mg) 
J01CR05 14 7 4.5 31.5 2.25 12.03 
Trimethoprim/ 
sulfamethoxazole 
DS tablet 
(Bactrim) (160 
mg) 
J01EE01 4 31 0.16 4.96 1.24 6.63 
Vancomycin 
(1000 mg) 
J01XA01 2 12 1 12 6.00 32.09 
Total: 90.16 482.15 
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To estimate the pharmaceutical costs due to unnecessary antibiotic use, the cost of each 
treatment regimen was calculated by multiplying the price of the dose of antibiotic given by the 
total number of doses given for the entire regimen, including the prescriptions filled upon 
discharge from the hospital. The price of each antibiotic was provided by the hospital’s 
purchasing records, and this information can be found in appendix C.  The total cost of 
antibiotics given to the ABU group was $512.45 for a total of 353 doses. This calculation 
includes discharge antibiotics as well as inpatient antibiotics. 
Table 18: Pharmaceutical costs of patients with ABU 
Antibiotic administered (dosage) Total number of 
doses 
Price per dose Total Antibiotic 
Cost 
Amoxicillin/ clavulanate (Augmentin) (875 
mg) 23 
$0.95 
$21.85 
Cefazolin (Ancef) (1000 mg)* 65 $0.67 $43.55 
Cefepime (1000 mg) 18 $4.22 $75.96 
Ceftriaxone (Rocephin) (1000 mg) 13 $1.16 $15.08 
Cefuroxime (250 mg)* 10 $0.28 $2.80 
Cephalexin (500 mg) 1 n/a n/a 
Ciprofloxacin (500 mg)* 49 $0.14 $6.86 
Meropenem (500 mg) 1 $5.52 $5.52 
Nitrofurantoin (100 mg) 86 $1.98 $170.28 
Piperacillin/ tazobactam (Zosyn) (2250 mg) 20 $3.45 $69.00 
Piperacillin/ tazobactam (Zosyn) (4500 mg) 7 $6.93 $48.51 
Trimethoprim/ sulfamethoxazole DS tablet 
(Bactrim) (160 mg)* 48 
$0.15 
$7.20 
Vancomycin (1000 mg)* 12 $3.82 $45.84 
Total: $512.45 
It is important to note that the antibiotics marked with an asterisk may be inaccurate. The 
dosages received were slightly different from the doses priced by the pharmacy for one or two 
patients receiving these drugs. These prices were therefore estimated based on the prices 
available. Cephalexin was given once, but no information was available for the price of this drug 
at the time of submission.  
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4.2.3 Questionable Group 
Of the 88 included patients, 11 patients (12.5% of included patients) were classified by the 
research team as “questionable” because documentation was not clear enough to indicate 
whether or not the patient had a UTI or ABU. There was either no documentation of 
symptoms or indications why the patient was diagnosed and treated with a UTI, or the 
patients had unspecific symptoms and it was unclear if other causes were responsible for 
these symptoms. These symptoms include altered mental status and fever. Some of these 
patients were dealing with strokes, falls with head injuries, medication changes, and 
alcohol withdrawal, but no conclusions could be drawn from medical records. The 
breakdown of patient symptoms and documentation is listed in the table below.  Two 
patients presented with both altered mental status and fever over 100 degrees.  
Similar organisms were isolated from the urine cultures of the patients in this group when 
compared to the other 2 groups. The most common organism was E. coli (54.5%), followed by 
E. faecalis and K. pneumoniae.  
Table 19: Organisms isolated from patients with a questionable UTI diagnosis 
Organisms in Urine No. Patients 
Escherichia coli 6 
Enterococcus faecalis 3 
Klebsiella pneumoniae 3 
Enterobacter clocae 1 
Streptococcus viridans 1 
Table 20: Symptoms seen in patients with a questionable UTI diagnosis 
Symptom No. Patients (%) 
Altered mental status 5 (45.5%) 
Fever > 100˚F 3 (27.3%) 
No documentation 5 (45.5%) 
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The charts were also reviewed to learn why the patient was cultured and treated. A 
distinct lack of documentation was observed, and no light could be shed on the appropriateness 
of the diagnosis and treatment. However, for those patients whose records had notes on the 
reasons why they were cultured and treated, like finding bacteria in a UA, drowsiness, or foul 
smelling urine and history of a UTI, are not criteria listed by the IDSA as reasons to screen or 
treat.  For all patients, there were not specific notes of screening versus treatment, so all reasons 
found are compiled together in the table below. 
Table 21: Reasons for screening and treatment for UTI in patients with questionable UTI diagnosis 
Reasons for UA/Culture and Treatment No. Patients (%) 
No documentation 8 (72.7%) 
Checked UA for hematuria,  found bacteria 1 (9.1%) 
Drowsiness 1 (9.1%) 
Bad smell/History of UTI 1 (9.1%) 
This group also shows a similar pattern of time passing between the time a culture was 
done and the time of antibiotic treatment initiation. 91% of patients received antibiotics the same 
day as their urine culture was done. Only 1 physician waited for the results to come back before 
beginning a treatment regimen. Those details are summarized in the table below: 
Table 22: Time between culture and treatment in patients with questionable UTI diagnosis 
Time between culture and treatment No. Patients (%) 
Treatment initiated at time of culture 10 (90.9%) 
Waited 2-4 days for results 1 (9.1%) 
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In total, the patients were treated for 58.7 antibiotic days and the length of stay for all 
patients was 157 days, which totals to 373.67 antibiotic-days/1000 patient days. 
The following table calculates the defined daily doses (DDD) and DDD/1000 patient-
days. The WHO DDD values were obtained from the WHO Collaborating Centre for Drugs 
Statistics Methodology.33  
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Table 23: Defined Daily Doses for patients with questionable UTI diagnosis 
Drug Code WHO DDD Total 
# 
Doses 
Dose in g Quantity 
dispensed 
(g) (Total 
# Doses x 
Dose in 
g) 
DDD's 
(Quantity 
Dispensed/WHO 
DDD) 
DDD/1000 
patient 
days 
Amoxicillin/ 
clavulanate 
(Augmentin) 
(875 mg) 
J01CR02 3 11 0.875 9.625 3.21 20.44 
Cefazolin 
(Ancef) (1000 
mg)* 
J01DB04 3 14 1 14 4.67 29.72 
Cefepime (1000 
mg) 
J01DE01 2 7 1 7 3.50 22.29 
Ceftriaxone 
(Rocephin) 
(1000 mg) 
J01DD04 2 4 1 4 2.00 12.74 
Cefuroxime (250 
mg)* 
J01DC02 3 3 0.25 0.75 0.25 1.59 
Ciprofloxacin 
(500 mg)* 
J01MA02 0.5 11 0.5 5.5 11.00 70.06 
Nitrofurantoin 
(50 mg) 
J01XE01 0.2 30 0.1 3 15.00 95.54 
Piperacillin/ 
tazobactam 
(Zosyn) (2250 
mg) 
J01CR05 14 9 2.25 20.25 1.45 9.21 
Piperacillin/ 
tazobactam 
(Zosyn) (4500 
mg) 
J01CR05 14 9 4.5 40.5 2.89 18.43 
Trimethoprim/ 
sulfamethoxazole 
DS tablet 
(Bactrim) (160 
mg)* 
J01EE01 4 30 1 30 7.50 47.77 
Vancomycin 
(1000 mg)* 
J01XA01 2 1 1 1 0.50 3.18 
Total: 51.96 330.98 
To estimate the pharmaceutical costs due to unnecessary antibiotic use, the cost of each 
treatment regimen was calculated by multiplying the price of the dose of antibiotic given by the 
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total number of doses given for the entire regimen, including the prescriptions filled upon 
discharge from the hospital. The price of each antibiotic was provided by the hospital’s 
purchasing records, and this information can be found in appendix C.  The total cost of 
antibiotics given to the questionable group was $271.76 for a total of 234 dosages. This includes 
both inpatient and discharge antibiotics. 
Table 24: Pharmaceutical costs of patients with questionable UTI diagnosis 
Antibiotic administered (dosage) Total number of 
doses 
Price per dose Total Antibiotic 
Cost 
Amoxicillin/ clavulanate (Augmentin) (875 mg) 58 $0.95 $55.10 
Cefazolin (Ancef) (1000 mg) 14 $0.67 $9.38 
Cefepime (1000 mg) 7 $4.22 $29.54 
Ceftriaxone (Rocephin) (1000 mg) 4 $1.16 $4.64 
Cefuroxime (250 mg) 11 $0.28 $3.08 
Ciprofloxacin (500 mg)* 27 $0.14 $3.78 
Nitrofurantoin (100 mg)* 30 $1.98 $59.4 
Piperacillin/ tazobactam (Zosyn) (2250 mg) 9 $3.45 $31.05 
Piperacillin/ tazobactam (Zosyn) (4500 mg) 9 $6.93 $62.37 
Trimethoprim/ sulfamethoxazole DS tablet 
(Bactrim) (160 mg)* 
64 $0.15 
$9.60 
Vancomycin (1000 mg) 1 $3.82 $3.82 
Total: $271.76 
It is important to note that the antibiotics marked with an asterisk may be inaccurate. The 
dosages received were slightly different from the doses priced by the pharmacy for one or two 
patients receiving these drugs. These prices were therefore estimated based on the prices 
available. 
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5.0  DISCUSSION 
5.1 SUMMARY OF RESULTS 
The three groups showed similar demographics and a similar range of organisms isolated from 
the urine culture. More emphasis will be put into the analysis of the ABU and questionable 
groups. A large portion of the patients in this group appears to have acquired their bacteriuria in 
the hospital, some from catheter use. Since catheter-acquired ABU is the most common hospital 
acquired infection, this comes as no surprise.  
The results indicate that at least 30% of patients in this cohort diagnosed with a UTI were 
asymptomatic and should not have received antibiotic treatment. However, if all of the patients 
who were classified as having a questionable UTI diagnosis were in reality asymptomatic, the 
percentage of patients who were treated in appropriately would be 42.5%. The antibiotics used 
on the patients with ABU cost the hospital $512.45 for 26 patients, but these costs could range 
upwards to $784.21 if the patients with a questionable diagnosis are included in the analysis. 
These unnecessary costs could have been saved by the facility if physicians and prescribers 
practiced stronger adherence to published IDSA screening and treatment guidelines. Antibiotic 
days per 1000 patient-days show that ABU group received a higher number of antibiotics 
proportionately than the questionable group. Data was not available to calculate patient days for 
patients with a clear UTI, which would have been the best comparison group. Because of the 
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unnecessary exposure to antibiotics these patients are at risk for colonization or proliferation of 
resistant bacteria, in the future they would be at higher risk of mortality due to resistant 
infections, longer lengths of hospitalization, and higher hospital bills. Both the ABU and 
questionable groups showed that there were several reasons physicians were culturing for 
treating these cases (foul smelling urine, weakness, low sodium, etc). Combined with the high 
rates of ABU, this suggests that physicians may need more education about the IDSA screening 
and treatment guidelines and may benefit from an intervention. 
The 30-42.5% range of unnecessary ABU treatment fits nicely into the range other 
studies have shown. The table below summarizes recent publications that have found that 
patients with ABU were treated with antibiotics inappropriately. 
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Table 25: Summary of ABU overtreatment rates found in literature 
Author Year Title of Paper 
% of study 
patients  with 
ABU  
% patients 
with ABU 
treated 
Bonnal et al.34 2008 
Bacteriuria in a Geriatric Hospital: 
Impact of an Antibiotic 
Improvement Program 49% 20.1% 
Cope et al.19 2009 
Inappropriate Treatment of 
Catheter-Associated Asymptomatic 
Bacteriuria in a Tertiary Care 
Hospital 58.6% 32% 
Chowdhury et 
al.35 2012 
Preventing the inappropriate 
treatment of asymptomatic 
bacteriuria at a community 
teaching hospital 83% 47% 
Dalen et al.28 2005 
An evaluation of the management 
of asymptomatic catheter-
associated bacteriuria and 
candiduria at The Ottawa Hospital 24.4% 52% 
Gandhi et al.30 2009 
Importance of Urinary Tract 
Infection to Antibiotic Use Among 
Hospitalized Patients 32.6% 100% 
Khawcharoenporn 
et al.36  2011 
Abnormal urinalysis finding 
triggered antibiotic prescription for 
asymptomatic bacteriuria in the ED 27% 20% 
Lin et al.31 2012 
Overtreatment of Enterococcal 
Bacteriuria 54% 32.8% 
Linares et al.18 2011 
Electronic Memorandum Decreases 
Unnecessary Antimicrobial Use for 
Asymptomatic Bacteruria and 
Culture-Negative Pyuria 73.6% 26% 
Pavese et al.37 2009 
Does an Educational Session With 
an Infectious Diseases Physician 
Reduce the Use of Inappropriate 
Antibiotic Therapy for Inpatients 
With Positive Urine Culture 
Results? A Controlled 
Before‐and‐After Study 54.8% 44.3% 
Silver et al.29 2009 
Positive urine cultures: a major 
cause of inappropriate 
antimicrobial use in hospitals 49% 64% 
Zabarsky et al.25 2008 
Sustained reduction in 
inappropriate treatment of 
asymptomatic bacteriuria in a long-
term care facility through and 
educational intervention 69.3% 67.6% 
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Our study design was most similar to that of Gandhi et al., who looked at patients with a 
UTI diagnosis to determine if they were true UTIs or asymptomatic, who found almost identical 
rates of patients treated for a UTI who were asymptomatic.30 This data adds to current literature 
that ABU overtreatment is factor in all healthcare facilities nationwide. Since some of the 
facilities in this table have undergone an intervention, this data may suggest that the UTH may 
also consider an intervention to increase knowledge of when to screen and treat to lower ABU 
treatment rates. 
5.2 ANTIBIOTIC STEWARDSHIP 
In response to the high rates of inappropriate use of antibiotics, the associated costs, and other 
harms, the concept of antimicrobial stewardship, endorsed by the Infectious Diseases Society of 
America (IDSA), was developed in an effort to ensure “appropriate selection, dosing, route, and 
duration of antimicrobial therapy” and improve patient outcomes in a healthcare setting by 
ensuring a proper diagnosis.17 The purpose of an antimicrobial stewardship program (ASP) is to 
optimize patient outcomes and minimize adverse events through “quality-of-care improvements 
and disease-based management rather than antibiotic management and overall cost savings.”5 
ASPs do this by following initiatives to help physicians choose the most appropriate drug, 
dosage, and duration of therapy in order to resolve a patient’s infection with minimal side effects 
and pressures for the selection of resistant strains.2 There are many different ASPs that 
healthcare facilities have begun to implement across the country with varying degrees of success. 
These methods include education, formulary restriction, prior approval programs, streamlining, 
antibiotic cycling, and computer assisted programs. 
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Studies have been conducted world-wide that have fully evaluated the effects of ASPs. 
These studies have shown that ASPs can reduce antibiotic usage, improve susceptibility patterns, 
decrease development of antimicrobial resistance, and reduce healthcare costs.5 Reviews have 
also shown that ASPs can effectively reduce the incidence of C. difficile infections.1  
The 2007 IDSA/SHEA Guidelines for Developing an Institutional Program to Enhance 
Antimicrobial Stewardship outlines 2 main strategies that should “provide the foundation for an 
antimicrobial stewardship program.”38 These two strategies are (1) prospective audit with 
intervention and (2) feedback and formulary restriction and preauthorization.38 These two 
strategies have been shown to be effective in a variety of facilities and for different types of 
infections. IDSA/SHEA also lists 8 elements that “may be considered and prioritized as 
supplements to the core active antimicrobial stewardship strategies based on local practice 
patterns and resources.”38 These 8 elements are education, guidelines and clinical pathways, 
antimicrobial cycling, antimicrobial order forms, combination therapy, streamlining or de-
escalation of therapy, dose optimization, and parenteral to oral conversion.38 These 2 core 
strategies and 8 elements will each be discussed further. 
5.2.1 Program Strategies and Elements 
PROSPECTIVE AUDIT WITH INTERVENTION AND FEEDBACK 
In this strategy, a member of the antibiotic stewardship team can review patient records 
to decide if physician’s antibiotic choices, doses, and lengths of duration were the best choices 
he/she could have made based upon current guidelines. The team member then discusses with 
the physician about how to best improve their prescription choices and reduce inappropriate 
antibiotic use.38 Although this method is labor intensive, it empowers physicians and is least 
51 
invasive into the patient treatment process. This is now the most popular technique found in 
hospitals that are developing ASPs in their facilities.39  
FORMULARY RESTRICTION AND PREAUTHORIZATION 
Formulary restriction refers to the removal of certain antibiotics completely from the 
pharmacy formulary so that no clinician can prescribe them to any patients. This is “the most 
direct method of influencing antibiotic utilization and containing drug costs.”2 Decisions of the 
specific drugs to maintain in the formulary should consider the local pathogen and resistance 
patterns. Drugs with similar targets and safety issues should be minimized, and costs, benefits, 
and toxicities should be considered when replacing an old drug with a newer but more expensive 
drug. Restricting the formulary can assist in containing costs and regulating prescribing 
practices, although it does not prevent overuse of broad-spectrum antibiotics.2 
Preauthorization, or a prior approval program, is a system that requires the prescriber to 
contact the antibiotic stewardship to receive approval for the use of particular antibiotic.38 These 
types of programs can be set up in a variety of ways: telephone approval systems where the 
prescriber  calls a mobile phone of the stewardship team to get approval, antibiotic order forms 
with written justification for use, or automatic stop orders where the stewardship team can order 
the discontinuation of inappropriate antibiotics.2 Preauthorization programs are “by far the most 
onerous interventions to physicians, but they are probably also the single most effective 
intervention to improve antibiotic use and decrease antibiotic costs.”2 A survey of physicians 
found that doctors are “less likely to prescribe restricted agents requiring preapproval.”24  
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ELEMENTS 
EDUCATION 
Although education is the cornerstone to any effective public health intervention, when it 
is the only  intervention, it is the least effective and has no long-term impact on changing  the 
behaviors of physicians and clinicians.1 Educational interventions come in many different forms, 
such as mailing or posting informational posters, newsletters, or emails, presenting information 
at staff conferences, lectures, or seminars, or dissemination of clinical guidelines.2 Education 
alone, without an active intervention to accompany it, is “only marginally effective and has not 
demonstrated as sustained impact.”38  
GUIDELINES AND CLINICAL PATHWAYS 
Interestingly, one of the suggested elements is the development of clinical practice 
guidelines or clinical pathways, similar to those  produced by the IDSA for ABU screening and 
treatment. Guidelines as well as development of clinical pathways are helpful to help “streamline 
the decision making process for clinicians”2 and help prescribers made good antibiotic choices 
for the best patient results.  As seen in the results presented here, the high percentage of people 
with ABU being treated inappropriately suggests that these guidelines are not being strictly 
followed. Physicians generally agree with the principles of the guidelines but dissemination of 
guidelines alone is not effective,2 and implementation of these guidelines seems to be where the 
breakdown occurs.38 Local development of guidelines specific to the area, taking local resistance 
patterns into account, can increase interest and engage  physicians  in the process and 
implementation of guidelines and clinical pathways. Providing physicians with feedback and 
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education on antibiotic use and patient outcomes can also help integrate guidelines and pathways 
into routine clinical decision making.38 
ANTIMICROBIAL CYCLING 
Antimicrobial cycling is a method that rotates different classes of antibiotics for a 
patient’s infection in an attempt to prevent the development of resistance to one antimicrobial 
class.38 Although this strategy has received a lot of attention, different groups show conflicting 
results for this method. There is insufficient data for the IDSA to make a recommendation for the 
use of antimicrobial cycling to prevent or reduce resistance.38  
ANTIMICROBIAL ORDER FORMS 
Antimicrobial order forms have been shown to be effective in reducing antibiotic use and 
can “facilitate implementation of practice guidelines.”38 Physicians fill out this form when they 
would like to start a patient on a new treatment; physicians also fill out this form when they 
would like to change agents, doses, or routes of administration. The antibiotic stewardship team 
reviews the orders, then grants or denies the request. Forms can require physician specific 
justification for the requested antibiotic as  the best choice.38 
COMBINATION THERAPY 
In combination therapy, multiple broad-spectrum antibiotics are administered 
simultaneously in the hopes of “reducing serious infections, improving clinical outcomes, and 
preventing resistance.”38 However, the IDSA feels that there is insufficient data to recommend 
this strategy as a component of an antibiotic stewardship program.38 
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STREAMLINING OR DE-ESCALATION OF THERAPY 
Streamlining or de-escalation of therapy refers to changing an initial antibiotic regimen, 
usually a broad-spectrum agent, to one that is more targeted toward the causative organism’s 
susceptibility and resistance profile after laboratory results are available.2,38 The ISDA 
recommends this for use due to data that shows this method is effective in preventing the 
emergence of resistance,2 reducing antimicrobial exposure, and saving the hospital substantial 
savings.38 
DOSE OPTIMIZATION 
The IDSA recommends a component of the antibiotic stewardship program that allows 
for optimization of dosages based on individual patient characteristics, causative organisms, site 
of infections, and pharmacokinetic and pharmacodynamics characteristics of the drug.38 Dose 
optimization helps physicians get feedback to change their antibiotic  choices based on these 
patient characteristics, which is a component of the feedback strategy previously discussed. 
PARENTERAL TO ORAL CONVERSION 
The IDSA recommends making a plan to switch patients from initial parenteral antibiotic 
treatment to oral treatments as soon as the patient’s condition allows. Studies show that this 
method can reduce the patient’s length of hospital stay and healthcare costs, because parenteral 
antibiotics are much more costly and difficult to deliver.38 The healthcare facility may consider 
creating a set of clinical guidelines to facilitate this conversion at a systemic level as a part of 
their stewardship program. 
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5.2.2 Interventions at Other Facilities for ABU Overtreatment 
The table below is a compilation of published studies of interventions to reduce treatment of 
ABU. There are very few published results of studies that have done interventions to specifically 
reduce the treatment of ABU in patients in healthcare facilities. All of the interventions described 
above have had success reducing the amount of antibiotics used for these patients. All of these 
interventions make use of informing physicians about treatment guidelines. However, all of these 
interventions only included educational components, which according to the IDSA is not very 
effective in changing long-term outcomes unless it is coupled with an active antibiotic 
stewardship intervention, and should only be included as an extra element, not standing alone. 
The conflicting success of these educational campaigns and the IDSA’s recommendations 
produces many new questions worthy of discussion. Is an educational intervention for ABU 
treatment sufficient in healthcare settings? Are these results sustainable without a stronger 
antibiotic stewardship program the 2 core strategies in place? Preauthorization, formulary 
restriction, and audit with feedback mechanisms have all shown to reduce antibiotic resistance, 
costs, and adverse outcomes for patients with other types of infections. Will educational 
campaigns be enough to affect these downstream outcomes in the population? Future research 
will need to be done to compare results achieved by all of these strategies to determine which 
type of intervention is most effective to address the problem of overuse of antibiotics for ABU. 
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Table 26: Summary of Existing Interventions to reduce inappropriate treatment of ABU 
First 
Author 
and Year Intervention Components 
Control group or Pre-
intervention 
Intervention group or Post-
Intervention Results 
Bonnal 
(2008)34 
Pocket cards with treatment guidelines; 
staff meetings, use of infectious diseases 
consultant and pharmacist to evaluate 
appropriateness of antibiotic treatment 
and provide feedback to physician 
Total duration of treatment 
per patient with ABU: 7.8 
+/- 3.2 days, total number of 
treatment days: 196, 20% of 
ABU cases treated 
Total duration of treatment per 
patient with ABU: 6.5 +/- 1.9 
days, total number of treatment 
days: 150, 18% of ABU cases 
treated 
Total reduction of antibiotic for 
all bacteriuria patients: 21%, 
significant when just comparing 
change for  patients with ABU 
(p=0.007) 
Chowdhury 
(2012)35 
Clinical vignettes highlighting ASB 
management and decision-making, 
pocket cards with IDSA guidelines, 
promotional letter sent to physicians to 
promote awareness of guidelines 
47% of asymptomatic 
patients treated; total costs 
of inappropriately treatment: 
$1200 
15% of asymptomatic patients 
treated; total costs of inappropriate 
treatment: $600 
Reduction in percentage of 
asymptomatic patients treated (p 
=0.04); reduction in total costs 
of inappropriate treatment 
Linares 
(2011)18 
 Electronic  memorandum  reminding 
physicians of evidence-based guidelines 
against treating ABU and culture-
negative pyuria in the charts of patients 
receiving antibiotics  
ABU patients received 6.3 
+/- 4.2 mean antimicrobial-
days 
ABU patients received 2.2 +/- 
3.06 mean antimicrobial days 
Absolute mean reduction of 4.1 
antimicrobial-days and relative 
reduction of 65% (p <0.001) 
Loeb 
(2005)40 
Small group sessions with nurses with 
case scenarios; treatment algorithms 
created and explained to physicians 
individually; pocket cards with 
algorithms; larger posters in nursing 
stations; symptom log for nurses 
Rate of antimicrobial use for 
suspected UTIs 1.59 per 
1000 resident days;  
proportion of total 
antibiotics prescribed for 
suspected UTIs: 39% 
Rate of antimicrobial use for 
suspected UTIs 1.17 courses per 
1000 resident days; proportion of 
total antibiotics prescribed for 
suspected UTIs: 28% 
Rate of antimicrobial use for 
suspected UTIs decreased over 
time; proportion of total 
antibiotics prescribed for 
suspected UTIs significantly 
lower in intervention group 
Pavese  
(2009)37 
Control: physicians given treatment 
guidelines and data report of on 
inappropriate antibiotic use for UTIs; 
Intervention: Infectious diseases 
physician presented 1-hour seminar and 
discussion for other physicians with 
presentation of guidelines and data 
Unnecessary antibiotic use 
for ABU: Pre-intervention: 
55.2%, Post-intervention: 
37.2% 
Unnecessary antibiotic use for 
ABU: Pre-intervention: 73.5% 
Post-intervention: 16.7%; Lower 
rate of inappropriate empirical 
antibiotic therapy for ABU: Pre-
intervention: 30.8%  Post-
intervention: 13.8% 
Difference between groups in 
unnecessary use for ABU 
(p=0.01); Difference in rate of 
inappropriate use of antibiotics 
for ABU in intervention group 
pre- and post- intervention 
(p=0.03) 
Zabarsky 
(2008)25 
Interviews and education sessions with 
nurses and prescribers about harms of 
unnecessary antibiotic use, pocket cards 
with treatment guidelines; larger cards 
by computer stations; follow-up 
educational sessions for nurses 
Overall rate of treatment of 
ABU: 1.7 per 1000 patient-
days;  total antimicrobial 
days of therapy: 167.7 per 
1000 patient-days 
Overall rate of treatment of ABU: 
0.6 per 1000 patient-days; total 
antimicrobial days of therapy: 
117.4 per 1000 patient-days 
Reduction in overall rate of 
treatment for ABU (p=0.002); 
reduction in total antimicrobial 
patient days of therapy 
(P<0.001) 
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5.2.3 Future Recommendations 
Based on the results, the facility could benefit from an antibiotic stewardship 
intervention. If the hospital is concerned about overuse of antibiotics for other types of 
infections throughout the facility and there are no mechanisms in place to curb excessive 
prescribing practices, the hospital should consider developing an antibiotic stewardship team. 
They should also consider establishing 1. an audit and feedback system or 2. a formulary 
restriction with preauthorization plan. These methods will produce important public health 
outcomes that will benefit the entire community. It should be noted that these strategies will be 
very costly and time consuming upfront, but will be cost-effective with time.. On the other 
hand, if the hospital is mostly concerned with the overtreatment of ABU, creating an 
educational campaign for physicians and nurses may be a good way to begin, especially if 
there is insufficient funding available to begin a stewardship program. The best way to 
determine the proper direction for the hospital to take is to engage the physicians, nurses, 
pharmacists, infection control units, administrations, and funders and create a dialogue of the 
facility’s priorities. Effective programs that target physicians recognized that they will not 
change their prescribing practices “unless they are both aware and in agreement with the 
changes that are being proposed.”24  
5.2.4 Limitations 
There are several limitations to this study. The main limitation is the retrospective studys 
design in which the research is dependent on the quality of documentation in the medical 
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records. Since the results of this investigation are hinged upon the presence or absence of UTI 
symptoms, missing information regarding a patient’s symptoms was interpreted as an 
asymptomatic patient. This could have affected the accuracy of the data so it appeared that there 
were more patients with ABU that are being treated inappropriately. This could result in an 
inaccurate representation of the need for education or an intervention in this facility. If this is not 
the case and patients are all symptomatic for UTIs and being treated appropriately, implementing 
an intervention or taking efforts to reduce overtreatment of ABU will not be an efficient use of 
resources.  Most clinical records accessed during this investigation were obtained from the 
database of handwritten chart notes that had been scanned into the electronic medical record 
system. The handwriting was often illegible or the scanning process made the documents 
“grainy” and difficult to read. Thus, human error could have been introduced during their 
interpretation.  
Also, assumptions had to be made about patients whose symptoms were unspecific and 
that could have been explained by other clinical causes. The investigator attempted to minimize 
this by excluding any patients that were found to have any other type of bacterial infection and 
by having all unclear patients reviewed by the clinical pharmacy specialists with expertise in 
chart review, medical terminology, records, and symptoms and the proper treatment for UTIs.  
Another limitation of this study is the inability to analyze the rates of adverse reactions 
due to antibiotics and susceptibility/resistance patterns of the organisms infecting the patients in 
the cohort. There is no approach to examine if  patients  experienced unnecessary exposure to 
antibiotics will experience a resistant infection later, experience longer hospital stays, increased 
mortality, or increased cost of care due to this infection, or a subsequent C. difficile infection.  
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The results of this study have several important public health implications. The findings 
show that publication of national treatment guidelines is insufficient for eliminating unnecessary 
antibiotic use for ABU in healthcare facilities. Educational interventions or establishing an 
antimicrobial stewardship programs within a hospital are better methods to reducing 
overtreatment and should be considered by this facility and all facilities across the nation. The 
most important component of either of these methods is that they take efforts to engage 
physicians and other prescribers. Physician support and involvement will directly impact the 
success of a program since they will be the recipient of any messages or programs; thus, 
components of the program need to directly address this specific group’s concerns. 
This study adds to the profile showing that ABU is unnecessarily treated all over the 
country and the world, in both large and medium scale facilities. More research needs to be done 
about how ABU is treated in smaller hospitals and rural communities, and how physicians 
interact with published treatment guidelines in their facilities. Separate issues may need to be 
addressed when investigating antibiotic overuse and initiating an intervention in these 
communities. 
5.2.5 Final Notes 
Although it is easy to say that physicians make mistakes that are costly to patients and the 
facility alike and that ASPs will save money, in reality there is grey area. Although overuse of 
antibiotics can cause antibiotic resistance, costs, and adverse effects, antibiotic use is good in 
many ways, and there are harmful effects that come from suboptimal treatment of a patient 
which need to be considered when implementing and evaluating an ASP.5 It is important to 
remember that “in the midst of discussing all of the negatives associated with antimicrobial 
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use it should not be lost that these drugs save lives… [Antimicrobials] are not cigarettes or 
cocaine: they are highly valuable life-saving therapeutic agents that have been designed 
to benefit mankind by being used.”1 
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6.0  CONCLUSION 
Although antibiotics are good for hospital patients, they can produce unwanted consequences. 
When 50% of all antibiotic use is unnecessary, it is important to look into each facility to find 
ways to improve antibiotic prescription practices to assure the highest quality of patient care. The 
study facility, like many other facilities nationwide, can improve patient outcomes by adhering 
more strictly to published treatment guidelines produced by the IDSA to lower use of antibiotics 
for ABU in inappropriate patient populations. Although 30% treatment rate of ABU is similar to 
findings in other published studies, this facility has a responsibility to its patients to implement 
evidence-based methods to decrease these rates and lower subsequent risks of adverse drug 
reactions, C. difficile infections, and the emergence of antibiotic resistance. ASPs or educational 
interventions can improve ABU treatment rates and improve patient outcomes and should be 
considered in this facility. 
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APPENDIX A 
CDC AND NHSN UTI DEFINITIONS
These definitions were published by the CDC and NHSN41 
Criterion Urinary Tract Infection (UTI) 
Asymptomatic Bacteremic Urinary Tract Infection (ABUTI) 
Patient with* or without an indwelling urinary catheter has no signs or symptoms (i.e., 
for any age patient, no fever (>38°C); urgency; frequency; dysuria; suprapubic 
tenderness; costovertebral angle pain or tenderness OR for a patient ≤1 year of age; no 
fever (>38°C core); hypothermia  (<36°C core); apnea; bradycardia; dysuria; lethargy; 
or vomiting)  
and 
 a positive urine culture of ≥105 CFU/ml with no more than 2 species of uropathogen 
microorganisms** (see Comments section below). 
and  
a positive blood culture with at least 1 matching uropathogen microorganism to  
the urine culture, or at least 2 matching blood cultures drawn on separate occasions if 
the matching pathogen is a common skin commensal.  
*Patient had an indwelling urinary catheter in place for >2 calendar days, with day of
device placement being Day 1, and catheter was in place when all elements of this 
criterion were first present together.  
**Uropathogen microorganisms are: Gram- negative bacilli, Staphylococcus spp., 
yeasts, beta-hemolytic Streptococcus spp., Enterococcus spp., G. vaginalis, Aerococcus 
urinae, and Corynebacterium (urease positive)+.  
+Report Corynebacterium (urease positive) as either Corynebacterium species 
unspecified (COS)  or as  C. urealyticum (CORUR) if so speciated. 
(See complete list of uropathogen microorganisms.) 
Other Urinary Tract Infection (OUTI) (kidney, ureter, bladder, urethra, or tissue 
surrounding the retroperineal or perinephric space) 
Other infections of the urinary tract must meet at least 1of the following criteria: 
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1. Patient has microorganisms isolated from culture of fluid (other than urine) or tissue
from affected site. 
2. Patient has an abscess or other evidence of infection seen on direct examination,
during an invasive procedure, or during a histopathologic examination. 
3.Patient has at least 2 of the following signs or symptoms: fever (>38°C), localized
pain*, or localized tenderness at the involved site* 
 and  
at least 1 of the following: 
a. purulent drainage from affected site
b. microorganisms cultured from blood that are compatible with suspected site of
infection 
c. imaging test evidence of infection (e.g., abnormal ultrasound, CT scan, magnetic
resonance imaging [MRI], or radiolabel scan [gallium, technetium]). 
* With no other recognized cause
4.Patient <1 year of age has at least 1 of the following signs or symptoms: fever (>38°C
core), hypothermia (<36°C core), apnea*, bradycardia*, lethargy*, or vomiting* 
and 
at least 1 of the following:  
a. purulent drainage from affected site
b. microorganisms cultured from blood that are compatible with suspected site of
infection 
c. imaging test evidence of infection, (e.g., abnormal ultrasound, CT scan, magnetic
resonance imaging [MRI], or radiolabel scan [gallium, technetium]). 
* With no other recognized cause
Comment •Report infections following circumcision in newborns as SST-CIRC.
Symptomatic Urinary Tract Infection (SUTI) 
Must meet at least 1of the following criteria 
1a Patient had an indwelling urinary catheter in place for > 2 calendar days, with day of 
device placement being Day 1, and catheter was in place time when all elements of this 
criterion were first present together.  
and  
at least 1 of the following signs or symptoms: fever (>38°C); suprapubic tenderness*;  
costovertebral angle pain or tenderness*  
and  
a positive urine culture of ≥105 colony-forming units (CFU)/ml with no more than 2 
species of microorganisms.  
-----------------------------------------------------------OR------------------------------------------- 
Patient had an indwelling urinary catheter in place for >2 calendar days and had it 
removed the day of or the day before all elements of this criterion were first present 
together  
and  
at least 1 of the following signs or symptoms: fever (>38°C); urgency*; frequency*; 
dysuria*; suprapubic tenderness*; costovertebral angle pain or tenderness* 
and  
a positive urine culture of ≥105 colony-forming units (CFU)/ml with no more than 2 
species of microorganisms.  
*With no other recognized cause
1b Patient did not have an indwelling urinary catheter in place at the time of or the day 
before all elements of this criterion were first present together 
and  
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has at least 1 of the following signs or symptoms: fever (>38°C) in a patient that is ≤65 
years of age; urgency*; frequency*; dysuria*; suprapubic tenderness*; costovertebral 
angle pain or tenderness* 
and  
a positive urine culture of ≥105 CFU/ml with no more than 2 species of microorganisms. 
*With no other recognized cause
2a Patient had an indwelling urinary catheter in place for >2 calendar days, with day of 
device placement being Day 1, and catheter was in place when all elements of this 
criterion were first present together  
and  
at least 1 of the following signs or symptoms: fever (>38°C);  
suprapubic tenderness*; costovertebral angle pain or tenderness* 
and  
at least 1 of the following findings: 
a. positive dipstick for leukocyte esterase and/or nitrite
b. pyuria (urine specimen with ≥10 white blood cells [WBC]/mm3 of unspun urine or >5
WBC/high power field of spun urine) 
c. microorganisms seen on Gram’s stain of unspun urine and a positive urine culture of
≥103and <105 CFU/ml with no more than 2 species of microorganisms.  
----------------------------------------------------------OR-------------------------------------------- 
Patient with an indwelling urinary catheter in place for >2 calendar days and had it 
removed the day of or the day before all elements of this criterion were first present 
together  
and  
at least 1 of the following signs or symptoms: fever (>38°C); urgency*; frequency*; 
dysuria*; suprapubic tenderness*; costovertebral angle pain or tenderness* 
and  
at least 1 of the following findings:  
a. positive dipstick for leukocyte esterase and/or nitrite
b. pyuria (urine specimen with ≥10 WBC/mm3of unspun urine or >5 WBC/high power
field of spun urine 
c. microorganisms seen on Gram’s stain of unspun urine and a positive urine culture of
≥103 and <105 CFU/ml with no more than 2 species of microorganisms. 
*With no other recognized cause
2b Patient did not have an indwelling urinary catheter in place at the time of, or the day 
before all elements of this criterion were first present together  
and  
has at least 1 of the following signs or symptoms: fever (>38°C) in a patient that is ≤65 
years of age; urgency*; frequency*; dysuria*; suprapubic tenderness*; costovertebral 
angle pain or tenderness*  
and  
at least 1 of the following findings:  
a. positive dipstick for leukocyte esterase and/or nitrite
b. pyuria (urine specimen with ≥10 WBC/mm 3 of unspun urine or >5 WBC/high power
field of spun urine 
c. microorganisms seen on Gram’s stain of unspun urine and a positive urine culture of
≥103 and <105 CFU/ml with no more than 2 species of microorganisms. 
*With no other recognized cause
3 Patient ≤1 year of age with**or without an indwelling urinary catheter  
has at least 1 of the following signs or symptoms: fever (>38°C core); hypothermia 
(<36°C core); apnea*; bradycardia*; dysuria*; lethargy*; vomiting* 
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and  
a positive urine culture of ≥105 CFU/ml with no more than 2 species of microorganisms. 
Elements of the criterion must occur within a timeframe that does not exceed a gap of 1 
calendar day. 
*With no other recognized cause
**Patient had an indwelling urinary catheter in place for >2 calendar days, with day of 
device placement being Day 1, and catheter was in place when all elements of this 
criterion were first present together.  
4 Patient ≤1 year of age with** or without an indwelling urinary catheter has at least 1 of 
the following signs or symptoms: fever (>38°C core); hypothermia (<36°C core); 
apnea*; bradycardia*; dysuria*; lethargy*; vomiting* 
and  
at least 1 of the following findings:  
a. positive dipstick for leukocyte  esterase and/or nitrite
b. pyuria (urine specimen with ≥10 WBC/mm3 of unspun urine or >5 WBC/high power
field of spun urine 
c. microorganisms seen on Gram’s stain of unspun urine and a positive urine culture of
between ≥103and <105CFU/ml with no more than two species of microorganisms. 
* With no other recognized cause
**Patient had an indwelling urinary catheter in place for >2 calendar days, with day of 
device placement being Day 1, and catheter was in place when all elements of this 
criterion were first present together.  
Comments • Elements of the criterion must occur within a timeframe that does not exceed a gap of
1 calendar day. 
• Laboratory cultures reported as “mixed flora” represent at least 2 species of organisms.
Therefore an additional organism recovered from the same culture, would represent >2 
species of microorganisms. Such a specimen cannot be used to meet the UTI criteria.  
• Urinary catheter tips should not be cultured and are not acceptable for the diagnosis of
a urinary tract infection. 
• Urine cultures must be obtained using appropriate technique, such as clean catch
collection or catheterization. Specimens from indwelling catheters should be aspirated 
through the disinfected sampling ports.  
• In infants, urine cultures should be obtained by bladder catheterization or suprapubic
aspiration; positive urine cultures from bag specimens are unreliable and should be 
confirmed by specimens aseptically obtained by catheterization or suprapubic 
aspiration. 
• Urine specimens for culture should be processed as soon as possible, preferably within
1 to 2 hours. If urine specimens cannot be processed within 30 minutes of collection, 
they should be refrigerated, or inoculated into primary isolation medium before 
transport, or transported in an appropriate urine preservative. Refrigerated specimens 
should be cultured within 24 hours.  
• Urine specimen labels should indicate whether or not the patient is symptomatic.
• Report secondary bloodstream infection = “Yes” for all cases of Asymptomatic
Bacteremic Urinary Tract Infection (ABUTI). 
• Report only pathogens in both blood and urine specimens for ABUTI.
•Report Corynebacterium (urease positive) as either  Corynebacterium species
unspecified (COS) or as C. urealyticum (CORUR) if speciated. 
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APPENDIX B 
ABU/UTI RETROSPECTIVE STUDY – DATA EXTRACTION FORM 
The data collection form used to record all data from medical records can be found below. 
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ABU/UTI RETROSPECTIVE STUDY – DATA 
EXTRACTION FORM 
Name:________________________________________ 
Account #: ____________________________________ 
MRN:_________________________________________ 
Identifier:_____________________________________ 
Age:_____      Gender (circle):   Male   /   Female 
ICD-9 Codes: 
____________________________________________ 
Exclusions Identified: 
□ ICU & urine culture on admission
□ Neutropenia
□ Taking antibiotics upon admittance
□ Concomitant infections requiring abx
□ Planned urological procedures
□ Pregnant
□ Duplicate urinary culture
Diagnostics performed: 
□ Urine culture □ Urinalysis (UA):  WBC= ____
Organisms Present and colony count in culture: 
_____________________________________________
_____________________________________________ 
Date collected:_________________________________ 
TREATMENT 
In Hospital 
Antibiotics(s):_________________________________ 
Dose & frequency:_____________________________ 
#Days:_______________________________________ 
At Discharge 
Antibiotics(s):_________________________________ 
Dose & frequency:_____________________________ 
#Days:_______________________________________ 
Symptoms present at time of culture or admit: 
□ Burning when urination □ Urinary frequency
□ Urinary urgency □ Flank pain
□ Suprapubic pain/ tenderness        □ AMS
□ Costovertebral angle tenderness
Signs present at time of culture or at admit: 
Serum WBC: __________ 
Temperature: _________ 
COMORBIDITIES/HISTORY: 
□ Diabetes mellitus □ HIV
□ UTI/pyelo (past 3 mo)
□ Benign prostatic hyperplasia
□ Spinal cord injury or paralysis
□ Ureteral reflux
□ Urinary tract obstruction
□ Catheter use and duration:
□ Indwelling: _____________________
□ In and Out: _____________________
□ Condom: _______________________
□ Other Comorbidities:
_____________________________________________
_____________________________________________ 
Any notes made on reason for treatment: 
_____________________________________________
_____________________________________________ 
DATA ANALYSIS 
□ Appropriate    /    Inappropriate     urine culture
□ Proper diagnosis of UTI (positive culture + at least 1
symptom) 
□ Improper diagnosis of UTI
□ Patient treated inappropriately with abx:
Cost of antibiotics x duration of treatment: = 
_____________________________________________ 
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APPENDIX C 
COSTS OF ANTIBIOTICS FROM UTH PHARMACY 
Inpatient Antibiotic Costs August 2012 
 
Antibiotic (IV) Cost  $ 
Cefazolin 1 gram 0.67 
Cefepime 1 gram 4.22 
Cefepime 2 grams 6.79 
Ceftriaxone 1 gram 1.16 
Ceftriaxone 2 grams 2.63 
Meropenem 500 mg 5.52 
Meropenem 1 gram 11.39 
Nafcillin 1 gram 10.39 
Nafcillin 2 grams 20.59 
Piperacillin/ tazobactam 4.5 grams 6.93 
Piperacillin/ tazobactam 2.25 grams 3.45 
Vancomycin 1 gram vial APP  3.82 
 
Baxter mini-bag plus piggybacks: 
NS 50 ml bag each $2.14 
NS 100 ml bag each $2.14 
 
Antibiotic (PO) Cost  $ 
Amoxicillin 250 mg capsule 0.09 
Amoxicillin 500 mg capsule 0.14 
Amoxicillin/ clavulanate 500 mg tablet 0.71 
Amoxicillin/ clavulanate 875 mg tablet 0.95 
Azithromycin 250 mg tablet 0.45 
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Cefuroxime axetil 250 mg tablet 0.28 
Ciprofloxacin 500 mg tablet 0.14 
Ciprofloxacin 750 mg tablet 0.29 
Doxycycline hyclate 100 mg capsule 0.04 
Nitrofurantoin BID 100 mg capsule 1.98 
Trimethoprim/ sulfamethoxazole DS tablet 0.15 
Vancomycin 125 mg capsule  18.50 
Vancomycin 250 mg capsule  35.92 
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